buprenorphine subdermal implant and pentobarbital both enhance sedation. Stay away from or Use Alternate Drug. Restrict use to patients for whom choice treatment method options are inadequate
pentobarbital will minimize the extent or influence of isradipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.
pentobarbital decreases levels of amphotericin B deoxycholate by inhibition of GI absorption. Applies only to oral type of both agents. Small/Significance Mysterious.
pentobarbital will lower the level or result of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
If struggling to prevent, double current pralsetinib dose starting on Working day 7 of coadministration with robust CYP3A inducer. Following inducer has been discontinued for at least fourteen days, resume past pralsetinib dose.
pentobarbital will lessen the website level or outcome of fosphenytoin by influencing hepatic enzyme CYP2C9/10 metabolism. Use Warning/Keep track of.
pentobarbital will lessen the level or impact of paclitaxel protein certain by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unknown.
pentobarbital will minimize the level or impact of alprazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will reduce the extent or result of bosentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Not known.
Contraindicated (1)pentobarbital will minimize the level or outcome of cariprazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is responsible for the development and elimination of cariprazine's active metabolites.
pentobarbital will minimize the extent or impact of cilostazol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will lessen the extent or result of ondansetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. No dosage adjustment for ondansetron is usually recommended for patients on these drugs.
pentobarbital will lower the extent or effect of mestranol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Contraindicated (one)pentobarbital will reduce the level or influence of lumacaftor/ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism.